Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Feverfew vs Semaglutide: Semaglutide has the stronger overall evidence (8.5 vs 5/10); the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Semaglutide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
100-300mg feverfew leaf/extract daily, standardized to ≥0.2-0.7% parthenolide (stable CO2 extract preferred)
with-meals
Standardized CO2 extract (parthenolide-standardized)
Prescription-only, clinician-titrated. Subcutaneous (Wegovy weight management: escalate to 2.4 mg once weekly; Ozempic diabetes: 0.5-2.0 mg once weekly). Oral (Rybelsus diabetes: 3-14 mg once daily). DO NOT self-dose.
any
Subcutaneous once-weekly injection (Ozempic / Wegovy)
4-12 weeks
4-8 weeks
Days
On discontinuation
Weeks to months
Months (titrated over 16-20 weeks)
Months to years
Especially during dose escalation
A Critical Approach to Evaluating Clinical Efficacy, Adverse Events and Drug Interactions of Herbal Remedies.
Phytotherapy research : PTR (2016) · Meta analysis
Critical appraisal of systematic-review/meta-analysis evidence
Feverfew for migraine prophylaxis: a systematic review.
Journal of dietary supplements (2009) · Systematic review
Some trials showed fewer migraine attacks
Feverfew for preventing migraine.
The Cochrane database of systematic reviews (2015) · Systematic review
Six trials (561 patients) met inclusion criteria, one new since the 2004 edition
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
N Engl J Med (2021) · Rct · n=1961
Double-blind RCT in 1,961 adults with obesity/overweight WITHOUT diabetes, randomized 2:1 to subcutaneous semaglutide 2.4 mg/week or placebo plus lifestyle for 68 weeks
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT).
N Engl J Med (2023) · Rct · n=17604
Large cardiovascular-outcomes RCT: 17,604 patients with preexisting cardiovascular disease and overweight/obesity but WITHOUT diabetes
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6).
N Engl J Med (2016) · Rct · n=3297
Pre-approval cardiovascular-safety RCT in 3,297 patients with type 2 diabetes at high cardiovascular risk, semaglutide (0.5/1.0 mg/week) vs placebo for 104 weeks
Semaglutide has a higher evidence score (8.5/10 vs 5/10) and wins in 2 of 3 categories.
No known interactions between Feverfew and Semaglutide have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.